In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.
Back
Breaking Down the New Dietary Guidelines 2025–2030: Evidence, Gaps, and Real-World Practice
A panel of experts examines the 2025–2030 Dietary Guidelines for Americans, unpacking what has changed, where controversy remains, and how these population-level recommendations translate into real-world patient care. The series explores key topics including protein intake, saturated fat, added sugars, fiber, pediatric nutrition, alcohol guidance, cultural dietary patterns, and food access, highlighting areas where visual messaging and written guidance may diverge. Emphasizing practical interpretation over rigid application, the series equips clinicians with insight into personalizing nutrition counseling across diverse patient populations while accounting for health equity, cultural context, and the realities of everyday clinical practice.
Breaking Down the New Dietary Guidelines 2025–2030: Evidence, Gaps, and Real-World Practice
Episodes
All
All
In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.
In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.
In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.
In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.
Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.
In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.
In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5